Cost-effectiveness of clopidogrel, prasugrel and ticagrelor for dual antiplatelet therapy after acute coronary syndrome: a decision-analytic model

BACKGROUND: The use of prasugrel or ticagrelor as part of dual antiplatelet therapy with acetylsalicylic acid after acute coronary syndrome (ACS) improves clinical outcomes relative to clopidogrel. The relative cost-effectiveness of these agents are unknown. We conducted an economic analysis evaluat...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:CMAJ Open
Main Authors: Abdel-Qadir, Husam, Roifman, Idan, Wijeysundera, Harindra C.
Formato: Artigo
Idioma:Inglês
Publicado: 8872147 Canada Inc. 2015
Assuntos:
Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4701656/
https://ncbi.nlm.nih.gov/pubmed/26770967
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.9778/cmajo.20150056
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares